Clinical Trial

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated July 22, 2022 (before its estimated August 2022 completion). Its status may not reflect the trial's current state.
Summary
This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-402, administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGA3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2016-10-13; most recent amendment 2022-07-20.
Status change: Recruiting → Active, Not Recruiting 2022-07-20
Status change: Not Yet Recruiting → Recruiting 2017-06-27
Trial Details
NCT Number NCT02935517
Lead Sponsor Beacon Therapeutics
Conditions Achromatopsia
Enrollment 24 participants
Start Date 2017-08-03
Primary Completion 2022-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2022-07-22